Personalis (NASDAQ:PSNL) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Personalis (NASDAQ:PSNL) had its price objective boosted by analysts at Needham & Company LLC from $12.00 to $17.00 in a research note issued on Friday, Marketbeat reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price would indicate a potential upside of 10.46% from the company’s current price.

A number of other analysts have also recently weighed in on the company. BTIG Research cut their price target on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. TD Cowen reissued a “buy” rating on shares of Personalis in a research report on Wednesday. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Morgan Stanley upped their price target on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $12.50.

Personalis Stock Down 1.2%

Shares of NASDAQ:PSNL opened at $15.39 on Friday. The firm’s 50 day moving average price is $10.94 and its 200 day moving average price is $8.90. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -15.09 and a beta of 2.24. Personalis has a fifty-two week low of $3.84 and a fifty-two week high of $16.39.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The firm had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $14.48 million. On average, equities analysts anticipate that Personalis will post -1.07 EPS for the current year.

Insider Buying and Selling at Personalis

In other Personalis news, CFO Aaron Tachibana sold 51,251 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the transaction, the chief financial officer owned 198,833 shares of the company’s stock, valued at approximately $2,620,618.94. This trade represents a 20.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.15, for a total value of $1,315,000.00. Following the sale, the chief executive officer owned 235,986 shares in the company, valued at $3,103,215.90. This trade represents a 29.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 435,032 shares of company stock valued at $5,599,929 in the last 90 days. 4.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Aberdeen Group plc grew its position in Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares during the last quarter. Howland Capital Management LLC increased its stake in Personalis by 65.5% in the fourth quarter. Howland Capital Management LLC now owns 547,115 shares of the company’s stock valued at $4,355,000 after purchasing an additional 216,442 shares during the period. Next Century Growth Investors LLC purchased a new stake in shares of Personalis in the fourth quarter valued at about $4,970,000. D.A. Davidson & CO. purchased a new stake in shares of Personalis in the fourth quarter valued at about $1,158,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Personalis in the fourth quarter valued at about $2,308,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.